Market Cap 44.09M
Revenue (ttm) 35.59M
Net Income (ttm) -20.72M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -58.22%
Debt to Equity Ratio 1.62
Volume 31,300
Avg Vol 123,402
Day's Range N/A - N/A
Shares Out 62.80M
Stochastic %K 58%
Beta 1.32
Analysts Strong Sell
Price Target $5.56

Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediator...

Industry: Medical Devices
Sector: Healthcare
Phone: 732 329 8885
Fax: 732 329 8650
Address:
305 College Road East, Princeton, United States
B2iDigital
B2iDigital Jan. 15 at 10:05 PM
Vision changes after a stroke can develop gradually and go unnoticed during recovery. Vycor’s NovaVision division provides a free online visual field screening tool that help stroke survivors check for potential changes and support informed conversations with their healthcare providers. Vycor Medical, Inc. (OTCQB: $VYCO) is a B2i Digital Featured Company. See the company’s complete profile at https://b2idigital.com/vycor-medical. In a new blog post, Vycor discusses five practical reasons online screening can be valuable, including accessibility and convenience, as well as early awareness of issues. As the article notes: “Screening results give you concrete information to discuss with your healthcare team. Rather than describing vague concerns about your vision, you can share screening results that show specific patterns.” Read the entire article here: https://novavision.com/five-reasons-to-consider-online-visual-field-screening/ Vycor operates two divisions: Vycor Medical (ViewSite Brain Access System™ for neurosurgery) and NovaVision (vision rehabilitation therapies for stroke and brain injury patients). The company is led by CEO Peter Zachariou, President David Cantor, and CFO Adrian Liddell, each bringing extensive experience in medical technology, business development, and finance. More information is available at https://vycormedical.com/investors/. For investor inquiries, please contact [email protected]. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased and currently owns shares of unrestricted VYCO stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of VYCO or any security, nor is it intended to offer any opinion on VYCO as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $CTSO, $SNWV, $IHI
2 · Reply
ZacksSCR
ZacksSCR Jan. 13 at 6:10 PM
$CTSO: CytoSorbents Price Target Increased to $5.00 Based on Higher Than Expected Gross Margins https://buff.ly/8xeFDUu
0 · Reply
DARKP00L
DARKP00L Jan. 12 at 2:18 PM
$CTSO 09:00 on Jan. 12 2026 What Analysts Are Saying About CytoSorbents Stock #tradeideas
0 · Reply
DARKP00L
DARKP00L Jan. 12 at 12:36 PM
$CTSO 07:25 on Jan. 12 2026 CytoSorbents Expects Q4 Revenue To Be ~$9.2M And FY25 Revenue Of ~$37M, With Expected Q4 Gross Margins In Range Of 73%-75% #tradeideas
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 6 at 12:50 AM
$CTSO RSI: 47.53, MACD: -0.0206 Vol: 0.04, MA20: 0.68, MA50: 0.72 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
hanovk68
hanovk68 Jan. 5 at 10:29 PM
$CTSO PC might be purchasing shares on the open market to show his confidence in the future performance of the company; however, it’s notable that his board members have not been following his lead. This is far more telling to me.
0 · Reply
okeydokey_artichokey
okeydokey_artichokey Jan. 4 at 5:17 PM
$CTSO Pivot to selling tee-shirts on the boardwalk.
0 · Reply
hanovk68
hanovk68 Dec. 30 at 4:26 PM
$CTSO so, in keeping with prior patterns, the share has now dropped below Phil Chan’s most recent open market purchase price signaling that he has continuously been unable to set a floor under the share price. Hard to imagine that a reverse split is not in the Company’s future in 2026
0 · Reply
NJ125
NJ125 Dec. 30 at 8:41 AM
$CTSO sometimes companies get delisted for failing rules like the $1 bid price for 30 days
0 · Reply
NJ125
NJ125 Dec. 30 at 8:39 AM
$CTSO year end employee count? Germany sales force issues? how many months of operating cash left?
0 · Reply
Latest News on CTSO
Cytosorbents Corporation (CTSO) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 7:21 PM EST - 2 months ago

Cytosorbents Corporation (CTSO) Q3 2025 Earnings Call Transcript


CytoSorbents Provides DrugSorb-ATR Regulatory Update

Sep 16, 2025, 7:00 AM EDT - 4 months ago

CytoSorbents Provides DrugSorb-ATR Regulatory Update


CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR

Aug 20, 2025, 7:00 AM EDT - 5 months ago

CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR


CytoSorbents Leads a New Era in Sepsis Treatment

Jul 31, 2025, 7:00 AM EDT - 6 months ago

CytoSorbents Leads a New Era in Sepsis Treatment


Cytosorbents Corporation (CTSO) Q1 2025 Earnings Call Transcript

May 14, 2025, 9:37 PM EDT - 8 months ago

Cytosorbents Corporation (CTSO) Q1 2025 Earnings Call Transcript


CytoSorbents Provides Regulatory Update for DrugSorb-ATR

May 1, 2025, 4:15 PM EDT - 9 months ago

CytoSorbents Provides Regulatory Update for DrugSorb-ATR


Cytosorbents Corporation (CTSO) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 7:51 PM EDT - 10 months ago

Cytosorbents Corporation (CTSO) Q4 2024 Earnings Call Transcript


CytoSorbents Secures $20 Million Credit Facility

Jul 2, 2024, 7:00 AM EDT - 1 year ago

CytoSorbents Secures $20 Million Credit Facility


B2iDigital
B2iDigital Jan. 15 at 10:05 PM
Vision changes after a stroke can develop gradually and go unnoticed during recovery. Vycor’s NovaVision division provides a free online visual field screening tool that help stroke survivors check for potential changes and support informed conversations with their healthcare providers. Vycor Medical, Inc. (OTCQB: $VYCO) is a B2i Digital Featured Company. See the company’s complete profile at https://b2idigital.com/vycor-medical. In a new blog post, Vycor discusses five practical reasons online screening can be valuable, including accessibility and convenience, as well as early awareness of issues. As the article notes: “Screening results give you concrete information to discuss with your healthcare team. Rather than describing vague concerns about your vision, you can share screening results that show specific patterns.” Read the entire article here: https://novavision.com/five-reasons-to-consider-online-visual-field-screening/ Vycor operates two divisions: Vycor Medical (ViewSite Brain Access System™ for neurosurgery) and NovaVision (vision rehabilitation therapies for stroke and brain injury patients). The company is led by CEO Peter Zachariou, President David Cantor, and CFO Adrian Liddell, each bringing extensive experience in medical technology, business development, and finance. More information is available at https://vycormedical.com/investors/. For investor inquiries, please contact [email protected]. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased and currently owns shares of unrestricted VYCO stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of VYCO or any security, nor is it intended to offer any opinion on VYCO as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $CTSO, $SNWV, $IHI
2 · Reply
ZacksSCR
ZacksSCR Jan. 13 at 6:10 PM
$CTSO: CytoSorbents Price Target Increased to $5.00 Based on Higher Than Expected Gross Margins https://buff.ly/8xeFDUu
0 · Reply
DARKP00L
DARKP00L Jan. 12 at 2:18 PM
$CTSO 09:00 on Jan. 12 2026 What Analysts Are Saying About CytoSorbents Stock #tradeideas
0 · Reply
DARKP00L
DARKP00L Jan. 12 at 12:36 PM
$CTSO 07:25 on Jan. 12 2026 CytoSorbents Expects Q4 Revenue To Be ~$9.2M And FY25 Revenue Of ~$37M, With Expected Q4 Gross Margins In Range Of 73%-75% #tradeideas
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 6 at 12:50 AM
$CTSO RSI: 47.53, MACD: -0.0206 Vol: 0.04, MA20: 0.68, MA50: 0.72 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
hanovk68
hanovk68 Jan. 5 at 10:29 PM
$CTSO PC might be purchasing shares on the open market to show his confidence in the future performance of the company; however, it’s notable that his board members have not been following his lead. This is far more telling to me.
0 · Reply
okeydokey_artichokey
okeydokey_artichokey Jan. 4 at 5:17 PM
$CTSO Pivot to selling tee-shirts on the boardwalk.
0 · Reply
hanovk68
hanovk68 Dec. 30 at 4:26 PM
$CTSO so, in keeping with prior patterns, the share has now dropped below Phil Chan’s most recent open market purchase price signaling that he has continuously been unable to set a floor under the share price. Hard to imagine that a reverse split is not in the Company’s future in 2026
0 · Reply
NJ125
NJ125 Dec. 30 at 8:41 AM
$CTSO sometimes companies get delisted for failing rules like the $1 bid price for 30 days
0 · Reply
NJ125
NJ125 Dec. 30 at 8:39 AM
$CTSO year end employee count? Germany sales force issues? how many months of operating cash left?
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 29 at 8:32 PM
$CTSO Share Price: $0.67 Contract Selected: Aug 21, 2026 $7.5 Calls Buy Zone: $0.04 – $0.05 Target Zone: $0.07 – $0.09 Potential Upside: 76% ROI Time to Expiration: 234 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
DARKP00L
DARKP00L Dec. 16 at 6:22 PM
$CTSO 13:03 on Dec. 16 2025 D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target #tradeideas
1 · Reply
JarvisFlow
JarvisFlow Dec. 16 at 6:03 PM
D. Boral Capital has updated their rating for CytoSorbents ( $CTSO ) to Buy with a price target of 10.
1 · Reply
melodicalmind
melodicalmind Dec. 16 at 3:04 AM
$CTSO might be, relatively, one of the safest micro-cap convictions right now. Real people with proven background, trying to solve real problems. Impressed.
1 · Reply
NJ125
NJ125 Dec. 10 at 10:50 PM
$CTSO toilet bound European German order ? What is happening to U.S. employee count?
1 · Reply
Kenzo71
Kenzo71 Dec. 2 at 2:22 PM
$CTSO has now closed below one dollar per share every day since August 20, 2025. That equates to 104 days. The Delisting watch has begun. !
1 · Reply
Steelometer
Steelometer Nov. 24 at 7:46 PM
$CTSO What is going on the Last 3 Trading Days?
2 · Reply
ZacksSCR
ZacksSCR Nov. 17 at 2:26 PM
$CTSO: CytoSorbents High Margin Revenue Growth Supports Price Target of $4.00 https://buff.ly/20ySDCO
0 · Reply
JarvisFlow
JarvisFlow Nov. 14 at 8:45 PM
D. Boral Capital has adjusted their stance on CytoSorbents ( $CTSO ), setting the rating to Buy with a target price of 10.
1 · Reply
JarvisFlow
JarvisFlow Nov. 14 at 1:08 PM
HC Wainwright & Co. updates rating for CytoSorbents ( $CTSO ) to Neutral, target set at 1 → 0.75.
0 · Reply